Stay updated on Amivantamab & Lazertinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe page’s footer revision label has been incremented from v3.5.2 to v3.5.3, indicating a minor software/UI update rather than a change to the underlying clinical trial record.SummaryDifference0.1%

- Check10 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedPublications section updated: replaced the 2025 online-ahead-of-print citation with the 2026 J Thorac Oncol article by Chen MF et al.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.1%

- Check53 days agoChange DetectedThe bottom revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check60 days agoChange DetectedAdded a new publication citation for Chen MF et al., Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases. J Thorac Oncol. 2025 Oct 23:103505. Removed the earlier print-entry citation (S1556-0864(25)02859-X) in PubMed publications.SummaryDifference0.1%

Stay in the know with updates to Amivantamab & Lazertinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.